[Skip to Content]
[Skip to Content Landing]
Editor's Note
May 2018

Pharmacogenetics and the Promise of Personalized Medicine

Author Affiliations
  • 1Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts
JAMA Cardiol. 2018;3(5):408. doi:10.1001/jamacardio.2018.0586

Pharmacogenetic interactions epitomize personalized medicine; a patient’s genetic makeup affects how he or she responds to a treatment. However, usually a robust overall effect of the pharmacotherapy is required to detect heterogeneity in response. For that reason, cholesteryl ester transfer protein (CETP) inhibitor medications would seem to be unlikely candidates for pharmacogenetic interactions. Indeed, the first 3 trials of CETP inhibitors failed to show a benefit. Most recently, though, the HPS3/TIMI 55 Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial,1 which had sufficient size and duration, showed a benefit to the CETP inhibitor anacetrapib proportional to the modest degree that anacetrapib lowered low-density lipoprotein cholesterol.